how do glp-1 inhibitors work Why are agonists being used to treat patients with nonalcoholic fatty liver disease? Current Insights, Advantages and Challenges
Description
The trials primarily included individuals with preexisting cardiovascular disease, which may limit the applicability of the results to a broader audience
10.1007/s00125-023-06053-9
After reviewing all clinical data for the medicine and consulting with regulators, Pfizer decided to halt research on it
8 This is a predictable effect of stopping a medicine intended for a chronic condition
Matrine, as a CaSR agonist promotes intestinal GLP-1 secretion and improves insulin resistance in diabetes mellitus
